Do You Have Hearing Loss?CLINICAL STUDY: Our clinic is testing an investigational drug called FX-322 that aims to repairdamaged sensory cells needed for hearing. Restoring these cells may result in improved hearingfor patients.To participate in this research study with FX-322: You must be a male or female adult, 18 to 65 years. Have an established diagnosis of stable sensorineural hearing loss by standard hearing tests.How does FX-322 Work?FX-322 is being developed by Frequency Therapeutics, Inc. for the treatment of hearing loss. FX-322 is a combinationof two different medications, injected through the eardrum allowing FX-322 to enter the inner ear where sensory cellsare located. This is a very fast procedure (the actual injection takes seconds, and the entire procedure under 15 minutes).Such injections are very common, are performed in the offices of ear, nose and throat doctors, and are well tolerated bypatients.Who is paying for this study?The study is being funded by Frequency Therapeutics, Inc., a company dedicated to developing treatments for themost common form of hearing loss. There will be no cost to your insurance company to be in this study. FrequencyTherapeutics, Inc. will pay for the costs of the study drug, study-related tests and procedures and study visits.Contact InformationIf you want any further information concerning this study, you can contact thePrincipal study doctor at 804-330-5501 or Studies@RichmondENT.com.Ask Us About FX-322 Today!CENTEN(ENTENT Do You Have Hearing Loss? CLINICAL STUDY: Our clinic is testing an investigational drug called FX-322 that aims to repair damaged sensory cells needed for hearing. Restoring these cells may result in improved hearing for patients. To participate in this research study with FX-322:  You must be a male or female adult, 18 to 65 years.  Have an established diagnosis of stable sensorineural hearing loss by standard hearing tests. How does FX-322 Work? FX-322 is being developed by Frequency Therapeutics, Inc. for the treatment of hearing loss. FX-322 is a combination of two different medications, injected through the eardrum allowing FX-322 to enter the inner ear where sensory cells are located. This is a very fast procedure (the actual injection takes seconds, and the entire procedure under 15 minutes). Such injections are very common, are performed in the offices of ear, nose and throat doctors, and are well tolerated by patients. Who is paying for this study? The study is being funded by Frequency Therapeutics, Inc., a company dedicated to developing treatments for the most common form of hearing loss. There will be no cost to your insurance company to be in this study. Frequency Therapeutics, Inc. will pay for the costs of the study drug, study-related tests and procedures and study visits. Contact Information If you want any further information concerning this study, you can contact the Principal study doctor at 804-330-5501 or Studies@RichmondENT.com. Ask Us About FX-322 Today! CENT EN (ENT ENT

Date: May 13, 2020

Active Ad

This ad expires on
June 12, 2020 (11 days)
more_vert

Richmond ENT

Shop Local / Essential Business

Call
Call (804) 330-5501
Directions
Get directions to this
location on Google Maps.
Website
Open website
in new tab.

Text

Do You Have Hearing Loss? CLINICAL STUDY: Our clinic is testing an investigational drug called FX-322 that aims to repair damaged sensory cells needed for hearing. Restoring these cells may result in improved hearing for patients. To participate in this research study with FX-322: You must be a male or female adult, 18 to 65 years. Have an established diagnosis of stable sensorineural hearing loss by standard hearing tests. How does FX-322 Work? FX-322 is being developed by Frequency Therapeutics, Inc. for the treatment of hearing loss. FX-322 is a combination of two different medications, injected through the eardrum allowing FX-322 to enter the inner ear where sensory cells are located. This is a very fast procedure (the actual injection takes seconds, and the entire procedure under 15 minutes). Such injections are very common, are performed in the offices of ear, nose and throat doctors, and are well tolerated by patients. Who is paying for this study? The study is being funded by Frequency Therapeutics, Inc., a company dedicated to developing treatments for the most common form of hearing loss. There will be no cost to your insurance company to be in this study. Frequency Therapeutics, Inc. will pay for the costs of the study drug, study-related tests and procedures and study visits. Contact Information If you want any further information concerning this study, you can contact the Principal study doctor at 804-330-5501 or Studies@RichmondENT.com. Ask Us About FX-322 Today! CENT EN (ENT ENT Do You Have Hearing Loss? CLINICAL STUDY: Our clinic is testing an investigational drug called FX-322 that aims to repair damaged sensory cells needed for hearing. Restoring these cells may result in improved hearing for patients. To participate in this research study with FX-322: You must be a male or female adult, 18 to 65 years. Have an established diagnosis of stable sensorineural hearing loss by standard hearing tests. How does FX-322 Work? FX-322 is being developed by Frequency Therapeutics, Inc. for the treatment of hearing loss. FX-322 is a combination of two different medications, injected through the eardrum allowing FX-322 to enter the inner ear where sensory cells are located. This is a very fast procedure (the actual injection takes seconds, and the entire procedure under 15 minutes). Such injections are very common, are performed in the offices of ear, nose and throat doctors, and are well tolerated by patients. Who is paying for this study? The study is being funded by Frequency Therapeutics, Inc., a company dedicated to developing treatments for the most common form of hearing loss. There will be no cost to your insurance company to be in this study. Frequency Therapeutics, Inc. will pay for the costs of the study drug, study-related tests and procedures and study visits. Contact Information If you want any further information concerning this study, you can contact the Principal study doctor at 804-330-5501 or Studies@RichmondENT.com. Ask Us About FX-322 Today! CENT EN (ENT ENT

Other Ads

codeEmbed

Ads Widget

close

Widget URL

Embed Code

Embed these ads anywhere HTML code is accepted by pasting the snippet below.